rizatriptan benzoate NDC 33342-093

NDC codes

FDA NDC Directory

Product NDC (as listed)33342-093Labeler and product segments. Claims need a package NDC.

Product NDC at billing width33342-0093Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package
33342-093-04	33342009304	12 TABLET, ORALLY DISINTEGRATING in 1 CONTAINER (33342-093-04)Marketed from Feb 27, 2023
33342-093-07	33342009307	30 TABLET, ORALLY DISINTEGRATING in 1 CONTAINER (33342-093-07)Marketed from Sep 23, 2014
33342-093-12	33342009312	10 BLISTER PACK in 1 CARTON (33342-093-12) / 10 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACKMarketed from Sep 23, 2014
33342-093-23	33342009323	18 TABLET, ORALLY DISINTEGRATING in 1 CONTAINER (33342-093-23)Marketed from Feb 27, 2023
33342-093-41	33342009341	3 BLISTER PACK in 1 CARTON (33342-093-41) / 6 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACKMarketed from Jun 4, 2018
33342-093-45	33342009345	2 BLISTER PACK in 1 CARTON (33342-093-45) / 6 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACKMarketed from Dec 19, 2018
33342-093-46	33342009346	200 TABLET, ORALLY DISINTEGRATING in 1 CONTAINER (33342-093-46)Marketed from Sep 23, 2014
33342-093-48	33342009348	4 POUCH in 1 CARTON (33342-093-48) / 1 BLISTER PACK in 1 POUCH / 10 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACKMarketed from Sep 23, 2014
33342-093-52	33342009352	1 BLISTER PACK in 1 CARTON (33342-093-52) / 3 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACKMarketed from Feb 13, 2017
33342-093-72	33342009372	6 BLISTER PACK in 1 CARTON (33342-093-72) / 3 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACKMarketed from Feb 13, 2017
33342-093-73	33342009373	3 BLISTER PACK in 1 CARTON (33342-093-73) / 3 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACKMarketed from Feb 13, 2017

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): rizatriptan benzoate
Generic name (nonproprietary): rizatriptan benzoate
Active ingredients: Rizatriptan benzoate — 5 mg/1
Dosage form: Tablet, Orally disintegrating
Route: Oral
Labeler: Macleods Pharmaceuticals Limited
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 203146
Marketing start: Sep 23, 2014
Listing expires: Dec 31, 2026
Other FDA classes: Serotonin 1b Receptor Agonists (Mechanism)Serotonin 1d Receptor Agonists (Mechanism)
Identifiers: Product ID 33342-093_137f6265-8c70-4748-a0d5-3976274e4ea0SPL ID 137f6265-8c70-4748-a0d5-3976274e4ea0SPL set ID 57ed2505-28f1-4292-b3c3-a49bf0f7c683RxCUI 312837, 312839UNII WR978S7QHHUPC 0333342094452, 0333342094414, 0333342094469, 0333342094520, 0333342093455, 0333342093417
Pharmacologic class: Serotonin-1b and Serotonin-1d Receptor Agonist

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N433342009304 followed by a unit qualifier and the quantity

Package 33342-0093-04. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Feb 27, 2023. This label includes a boxed warning.

Indications (excerpt from the label)

Rizatriptan benzoate orally disintegrating tablets are indicated for the acute treatment of migraine with or without aura in adults and in pediatric patients 6 to 17 years old. Limitations of Use • Rizatriptan benzoate orally disintegrating tablets should only be used where a clear diagnosis of migraine has been established. If a patient has no response for the first migraine attack treated with rizatriptan benzoate orally disintegrating tablets, the diagnosis of migraine should be reconsidered before rizatriptan benzoate tablets are administered to treat any subsequent attacks. • Rizatriptan benzoate orally disintegrating tablets are not indicated for use in the management of hemiplegic or …

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 203146

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 203146
Product	Strength	Form · route	Labeler	Product NDC
rizatriptan benzoate	Rizatriptan benzoate 10 mg/1	Tablet, Orally disintegratingOral	Macleods Pharmaceuticals Limited	33342-094
Rizatriptan Benzoate ODT	Rizatriptan benzoate 10 mg/1	Tablet, Orally disintegratingOral	Direct_rx	72189-609